Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemistry (60) 60
metallurgy (60) 60
organic chemistry (52) 52
peptides (52) 52
human necessities (50) 50
hygiene (50) 50
medical or veterinary science (50) 50
preparations for medical, dental, or toilet purposes (35) 35
specific therapeutic activity of chemical compounds ormedicinal preparations (30) 30
science & technology (24) 24
life sciences & biomedicine (19) 19
humans (18) 18
immunology (15) 15
biochemistry (14) 14
beer (13) 13
enzymology (13) 13
microbiology (13) 13
mutation or genetic engineering (13) 13
spirits (13) 13
vinegar (13) 13
wine (13) 13
animals (12) 12
compositions thereof (12) 12
culture media (12) 12
investigating or analysing materials by determining theirchemical or physical properties (12) 12
measuring (12) 12
mice (12) 12
microorganisms or enzymes (12) 12
physics (12) 12
propagating, preserving or maintaining microorganisms (12) 12
testing (12) 12
life sciences (10) 10
[sdv.imm]life sciences [q-bio]/immunology (8) 8
cancer (6) 6
abridged index medicus (5) 5
cells, cultured (5) 5
female (5) 5
immunotherapy (5) 5
killer cells, natural - immunology (5) 5
mesh: animals (5) 5
mesh: mice (5) 5
mice, inbred c57bl (5) 5
multidisciplinary sciences (5) 5
science & technology - other topics (5) 5
tumors (5) 5
apoptosis (4) 4
biological and medical sciences (4) 4
dendritic cells (4) 4
killer cells (4) 4
killer cells, natural - metabolism (4) 4
lymphocyte activation (4) 4
medical sciences (4) 4
membrane proteins - genetics (4) 4
mesh: humans (4) 4
natural killer cells (4) 4
oncology (4) 4
pharmaceutical industry (4) 4
t cells (4) 4
toll-like receptor 3 (4) 4
tumor necrosis factor ligand superfamily member 14 (4) 4
tumor necrosis factor-alpha - genetics (4) 4
analysis (3) 3
antibodies (3) 3
antineoplastic agents (3) 3
biochemistry & molecular biology (3) 3
cell biology (3) 3
cell line (3) 3
cell line, tumor (3) 3
cytotoxicity (3) 3
dendritic cells - immunology (3) 3
dendritic cells - metabolism (3) 3
dose-response relationship, drug (3) 3
hemic and immune systems (3) 3
immune system (3) 3
immunophenotyping (3) 3
killer cells, natural - drug effects (3) 3
killer cells, natural - pathology (3) 3
ligands (3) 3
male (3) 3
membrane glycoproteins - agonists (3) 3
mesh: toll-like receptor 3 (3) 3
mice, knockout (3) 3
middle aged (3) 3
monoclonal antibodies (3) 3
proteins (3) 3
research article (3) 3
t-lymphocyte subsets - immunology (3) 3
toll-like receptor 3 - metabolism (3) 3
toll-like receptor 7 - agonists (3) 3
virus diseases (3) 3
adult (2) 2
aged (2) 2
aminoquinolines - pharmacology (2) 2
antigens (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic combined chemotherapy protocols - pharmacology (2) 2
apoptosis - drug effects (2) 2
breast neoplasms (2) 2
breast neoplasms - metabolism (2) 2
cancer immunotherapy (2) 2
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (112) 112
French (37) 37
German (11) 11
Danish (4) 4
Spanish (2) 2
Chinese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Harnessing innate immunity in cancer therapy
by Demaria, Olivier and Cornen, Stephanie and Daeron, Marc and Morel, Yannis and Medzhitov, Ruslan and Vivier, Eric
Nature (London), ISSN 0028-0836, 10/2019, Volume 574, Issue 7776, pp. 45 - 56
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Care and treatment | Forecasts and trends | Immunotherapy | Cancer | DNA damage | Antibodies | Cytotoxicity | Innate immunity | Lymphocytes T | Genomes | Metastasis | Cancer therapies | Immunity | Pathways | Lymphocytes | Tumor necrosis factor-TNF | Deoxyribonucleic acid--DNA | Antigens | Immunoglobulins | Dendritic cells | Immunomodulation | Melanoma | Chimeric antigen receptors | Immune checkpoint | Ligands | Bispecific antibodies | Tumors | Apoptosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
by Perrot, Ivan and Michaud, Henri-Alexandre and Giraudon-Paoli, Marc and Augier, Séverine and Docquier, Aurélie and Gros, Laurent and Courtois, Rachel and Déjou, Cécile and Jecko, Diana and Becquart, Ondine and Rispaud-Blanc, Hélène and Gauthier, Laurent and Rossi, Benjamin and Chanteux, Stéphanie and Gourdin, Nicolas and Amigues, Beatrice and Roussel, Alain and Bensussan, Armand and Eliaou, Jean-François and Bastid, Jérémy and Romagné, François and Morel, Yannis and Narni-Mancinelli, Emilie and Vivier, Eric and Paturel, Carine and Bonnefoy, Nathalie
Cell reports (Cambridge), ISSN 2211-1247, 05/2019, Volume 27, Issue 8, pp. 2411 - 2425.e9
CD73 | CD39 | cancer immunotherapies | tumor micro-environment | immunosuppression | therapeutic antibodies | adenosine pathway | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Index Medicus | Life Sciences | Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
by Carvelli, Julien and Demaria, Olivier and Vély, Frédéric and Batista, Luciana and Chouaki Benmansour, Nassima and Fares, Joanna and Carpentier, Sabrina and Thibult, Marie-Laure and Morel, Ariane and Remark, Romain and André, Pascale and Represa, Agnès and Piperoglou, Christelle and Assante  Miranda, Laura and Baron, William and Belaid, Nourhène and Caillet, Clarisse and Caraguel, Flavien and Carrette, Barbara and Carrette, Florent and Chanuc, Fabien and Courtois, Rachel and Fenis, Aurore and Giordano, Marilyn and Girard-Madoux, Mathilde and Giraudon-Paoli, Marc and Gourdin, Nicolas and Grondin, Gwendoline and Guillot, Franceline and Habif, Guillaume and Jaubert, Solène and Lopez, Julie and Le Van, Mélanie and Lovera, Naouel and Mansuy, Marine and Bonnet, Elodie and Sansaloni, Audrey and Reboul, Annick and Mitry, Emmanuel and Nekkar-Constant, Camille and Péri, Valentine and Ricaut, Paul and Simon, Léa and Vallier, Jean-Baptiste and Vétizou, Marie and Zerbib, Robert and Ugolini, Sophie and Etiennot, Marion and Galluso, Justine and Lyonnet, Luc and Forel, Jean-Marie and Papazian, Laurent and Velly, Lionel and André, Baptiste and Briantais, Antoine and Faucher, Benoit and Jean, Estelle and Seguier, Julie and Veit, Veronique and Harlé, Jean-Robert and Pastorino, Boris and Delteil, Clémence and Daniel, Laurent and Boudsocq, Jean-Paul and Clerc, Axelle and Delmond, Emmanuel and Vidal, Pierre-Olivier and Savini, Hélène and Coutard, Bruno and Cordier, Pierre Yves and Le Dault, Erwan and Guervilly, Christophe and Simeone, Pierre and Gainnier, Marc and Morel, Yannis and Ebbo, Mikael and Schleinitz, Nicolas and Vivier, Eric and Explore COVID-19 Marseille Immunop and Explore COVID-19 IPH Grp and Explore COVID-19 Marseille Immunopole group and Explore COVID-19 IPH group and the Explore COVID-19 IPH group and the Explore COVID-19 Marseille Immunopole group
Nature (London), ISSN 0028-0836, 12/2020, Volume 588, Issue 7836, pp. 146 - 150
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | COVID-19 - immunology | Inflammation - pathology | Humans | Bronchoalveolar Lavage Fluid - immunology | Respiratory Distress Syndrome - immunology | Complement C5a - biosynthesis | Inflammation - complications | Respiratory Distress Syndrome - prevention & control | Acute Lung Injury - prevention & control | COVID-19 - complications | Inflammation - drug therapy | Myeloid Cells - immunology | COVID-19 - blood | Receptor, Anaphylatoxin C5a - immunology | SARS-CoV-2 - drug effects | Female | Myeloid Cells - drug effects | Respiratory Distress Syndrome - drug therapy | SARS-CoV-2 - immunology | Acute Lung Injury - drug therapy | Cytokine Release Syndrome - drug therapy | Disease Models, Animal | Cytokine Release Syndrome - immunology | Lung - pathology | CD11b Antigen - immunology | Cytokine Release Syndrome - prevention & control | Mice, Inbred C57BL | Inflammation - immunology | Complement C5a - antagonists & inhibitors | Animals | SARS-CoV-2 - pathogenicity | Receptor, Anaphylatoxin C5a - blood | Lung - drug effects | COVID-19 - pathology | Acute Lung Injury - immunology | Mice | Bronchoalveolar Lavage Fluid - chemistry | CD11b Antigen - metabolism | Complement C5a - immunology | Myeloid Cells - pathology | Receptor, Anaphylatoxin C5a - antagonists & inhibitors | Lung - immunology | Myeloid cells | Immune response | Complement component C5a | Severe acute respiratory syndrome | Viral diseases | Organs | Bronchus | Leukocytes (neutrophilic) | Inflammation | Coronaviruses | Blood | Recruitment | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Smoke inhalation | Receptors | Cell activation | Respiratory distress syndrome | Lungs | Bronchoalveolar lavage | Respiratory diseases | Monoclonal antibodies | Alveoli | Immune system | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
by André, Pascale and Denis, Caroline and Soulas, Caroline and Bourbon-Caillet, Clarisse and Lopez, Julie and Arnoux, Thomas and Bléry, Mathieu and Bonnafous, Cécile and Gauthier, Laurent and Morel, Ariane and Rossi, Benjamin and Remark, Romain and Breso, Violette and Bonnet, Elodie and Habif, Guillaume and Guia, Sophie and Lalanne, Ana Ines and Hoffmann, Caroline and Lantz, Olivier and Fayette, Jérôme and Boyer-Chammard, Agnès and Zerbib, Robert and Dodion, Pierre and Ghadially, Hormas and Jure-Kunkel, Maria and Morel, Yannis and Herbst, Ronald and Narni-Mancinelli, Emilie and Cohen, Roger B and Vivier, Eric
Cell (Cambridge), ISSN 0092-8674, 12/2018, Volume 175, Issue 7, pp. 1731 - 1743.e13
natural killer cells | CD8+ T cells | lymphocytes | cancer immunotherapy | inhibitory receptors | therapeutic monoclonal antibodies | immunce checkpoint inhibitor | CD8 | T cells | CD8(+) T cells | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | CD8-Positive T-Lymphocytes - pathology | NK Cell Lectin-Like Receptor Subfamily C - antagonists & inhibitors | Carcinoma, Squamous Cell - pathology | Humans | Carcinoma, Squamous Cell - therapy | Killer Cells, Natural - pathology | Cetuximab - therapeutic use | Carcinoma, Squamous Cell - immunology | NK Cell Lectin-Like Receptor Subfamily C - immunology | Animals | Immunity, Cellular - drug effects | Antineoplastic Agents, Immunological - therapeutic use | Immunotherapy | Killer Cells, Natural - immunology | Mice | CD8-Positive T-Lymphocytes - immunology | Clinical Trials, Phase II as Topic | Prevention | Fc receptors | Squamous cell carcinoma | Killer cells | Resveratrol | Monoclonal antibodies | Cancer | Index Medicus | Life Sciences | Immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Publisher Correction: Harnessing innate immunity in cancer therapy
by Demaria, Olivier and Cornen, Stephanie and Daeron, Marc and Morel, Yannis and Medzhitov, Ruslan and Vivier, Eric
Nature (London), ISSN 0028-0836, 12/2019, Volume 576, Issue 7785, pp. E3 - E3
Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
by Gauthier, Laurent and Morel, Ariane and Anceriz, Nadia and Rossi, Benjamin and Blanchard-Alvarez, Audrey and Grondin, Gwendoline and Trichard, Sylvia and Cesari, Cédric and Sapet, Melody and Bosco, Frédéric and Rispaud-Blanc, Hélène and Guillot, Franceline and Cornen, Stéphanie and Roussel, Alain and Amigues, Béatrice and Habif, Guillaume and Caraguel, Flavien and Arrufat, Sandrine and Remark, Romain and Romagné, François and Morel, Yannis and Narni-Mancinelli, Emilie and Vivier, Eric
Cell (Cambridge), ISSN 0092-8674, 06/2019, Volume 177, Issue 7, pp. 1701 - 1713.e16
natural killer cells | cancer immunotherapy | monoclonal antibodies | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Humans | Neoplasms, Experimental - therapy | Killer Cells, Natural - pathology | Antibodies, Bispecific - immunology | Antineoplastic Agents, Immunological - pharmacology | Neoplasms, Experimental - pathology | Antibodies, Bispecific - therapeutic use | Animals | Antigens, Ly - immunology | Antineoplastic Agents, Immunological - immunology | Immunoglobulin G - immunology | Neoplasms, Experimental - immunology | Immunoglobulin G - pharmacology | Killer Cells, Natural - immunology | Mice | Natural Cytotoxicity Triggering Receptor 1 - immunology | Cytotoxicity, Immunologic - drug effects | Viral antibodies | Killer cells | Analysis | Immunotherapy | Tumor antigens | Antibodies | T cells | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists
by Rajagopal, Deepa and Paturel, Carine and Morel, Yannis and Uematsu, Satoshi and Akira, Shizuo and Diebold, Sandra S
Blood, ISSN 0006-4971, 03/2010, Volume 115, Issue 10, pp. 1949 - 1957
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Biological and medical sciences | Medical sciences | Adjuvants, Immunologic - pharmacology | Imiquimod | Cancer Vaccines - pharmacology | Dendritic Cells - immunology | Melanoma, Experimental - metabolism | Quinolines - pharmacology | Dose-Response Relationship, Drug | Melanoma, Experimental - immunology | Interferon Type I - metabolism | Antineoplastic Agents - pharmacology | Interferon Type I - physiology | Receptor, Interferon alpha-beta - genetics | Imidazoles - therapeutic use | Tumor Cells, Cultured | Aminoquinolines - pharmacology | Dendritic Cells - metabolism | Toll-Like Receptor 7 - agonists | Melanoma, Experimental - therapy | Mice, Inbred C57BL | Membrane Glycoproteins - agonists | Imidazoles - pharmacology | Mice, Knockout | Animals | RNA - pharmacology | Mice | Aminoquinolines - therapeutic use | Index Medicus | Abridged Index Medicus | Immunobiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19
by Demaria, Olivier and Carvelli, Julien and Batista, Luciana and Thibult, Marie-Laure and Morel, Ariane and André, Pascale and Morel, Yannis and Vély, Frederic and Vivier, Eric
Cellular & molecular immunology, ISSN 1672-7681, 09/2020, Volume 17, Issue 9, pp. 995 - 997
Life Sciences & Biomedicine | Immunology | Science & Technology | Betacoronavirus - pathogenicity | T-Lymphocyte Subsets - immunology | NK Cell Lectin-Like Receptor Subfamily C - antagonists & inhibitors | Pandemics | Gene Expression - drug effects | Severe Acute Respiratory Syndrome - virology | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | NK Cell Lectin-Like Receptor Subfamily C - genetics | Severe Acute Respiratory Syndrome - immunology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Killer Cells, Natural - pathology | Case-Control Studies | Betacoronavirus - immunology | COVID-19 | NK Cell Lectin-Like Receptor Subfamily C - immunology | SARS-CoV-2 | Pneumonia, Viral - genetics | Killer Cells, Natural - immunology | Pneumonia - immunology | B-Lymphocytes - pathology | Molecular Targeted Therapy - methods | Pneumonia - genetics | Apyrase - antagonists & inhibitors | Antiviral Agents - therapeutic use | Apyrase - immunology | Coronavirus Infections - genetics | Severe Acute Respiratory Syndrome - drug therapy | B7-H1 Antigen - genetics | B7-H1 Antigen - immunology | Coronavirus Infections - immunology | Pneumonia - virology |